Literature DB >> 8706016

Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.

M Shimizu1, A Yamamoto, H Nakano, A Matsuzawa.   

Abstract

We have examined the effectiveness of a bacterial superantigen, staphylococcal enterotoxin B (SEB)-coupled tumor cells, to induce antitumor activity. SEB was chemically conjugated to tumor cells using a heterobifunctional cross-linking agent acting through NH2 and SH groups. V beta 8+ T cells were activated and increased in number after the culture with SEB-bound Meth A cells. The cultured T cells exhibited an antitumor activity in the Winn assay. Interleukin 2 (IL-2) receptor alpha + (IL-2R+) V beta 8+ T cells but not IL-2R+ V beta 6+ T cells increased in number in mice injected with SEB-bound Meth A cells. However, the percentages of V beta 8+ and V beta 6+ T cells did not change by this immunization. The antitumor effector cells were V beta 7- 8- CD4+ T cells. In vivo immunization with SEB-bound cells induced a strong antitumor activity, i.e., tumor-free mice/total mice = 14 of 15 (93%) for Meth A and 7 of 15 (47%) for hepatoma MH134. The induced antitumor activity was both dose dependent and tumor specific. Treatment with SEB-bound cells prolonged the survival days of Meth A-bearing mice by 62%. These results suggest that SEB-bound tumor cells may be a powerful method for induction of in vivo antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706016

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer.

Authors:  Motomu Shimizu; Akio Matsuzawa; Yasutaka Takeda
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  Sequential T cell response involved in tumor rejection of sarcoma, Meth A, in syngeneic mice.

Authors:  Y Jiao; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1998-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.